Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunology
Pharma
J&J's Tremya, Lilly's Ebglyss score in new patient groups
J&J tested Tremfya in psoriasis patients with involvement in "sensitive" areas, while Lilly weighed Ebglyss in eczema patients who've tried Dupixent.
Zoey Becker
Oct 25, 2024 11:00am
Organon pays up to $1.2B to acquire Dermavant and its drug Vtama
Sep 18, 2024 10:09am
J&J nixes Tremfya trial in giant cell arteritis
Jun 25, 2024 4:45pm
Asahi Kasei moves to buy Calliditas for more than $1B
May 28, 2024 11:19am
Lilly pads case for mirikizumab in its next potential indication
May 21, 2024 9:20am
Argenx isn't sweating over Vyvgart competitors: exec
May 9, 2024 4:56pm